| Risk | High |
|---|---|
| Min SIP Amount | ₹100 |
| Expense Ratio | 1.37% |
| NAV | ₹15.42 (07 Aug 2020) |
|---|---|
| Fund Started | 15 Jun 2018 |
| Fund Size | ₹1,523 Cr |
| Name | Sector | Instrument | % Assets |
|---|---|---|---|
| Cipla Ltd. | Healthcare | Equity | 10.8% |
| Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 9.9% |
| Lupin Ltd. | Healthcare | Equity | 7.3% |
| Biocon Ltd. | Healthcare | Equity | 4.4% |
| JB Chemicals & Pharmaceuticals Ltd. | Healthcare | Equity | 4.1% |
| Sanofi India Ltd. | Healthcare | Equity | 3.9% |
| Natco Pharma Ltd. | Healthcare | Equity | 3.9% |
| Cadila Healthcare Ltd. | Healthcare | Equity | 3.6% |
| Dr. Reddy's Laboratories Ltd. | Healthcare | Futures | 3.2% |
| Torrent Pharmaceuticals Ltd. | Healthcare | Equity | 3.0% |
ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct Growth is a Equity Mutual Fund Scheme launched by ICICI Prudential Mutual Fund. This scheme was made available to investors on 15 Jun 2018. Ihab Dalwai, Priyanka Khandelwal is the Current Fund Manager of ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹1,523 Cr and the Latest NAV as of 07 Aug 2020 is ₹15.42.
The ICICI Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund Direct Growth is rated High risk. Minimum SIP Investment is set to 100. Minimum Lumpsum Investment is 5000. Exit load of 1% if redeemed within 15 days.
To generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.However there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Returns are taxed at 15%, if you redeem before one year. After 1 year, you are required to pay LTCG tax of 10% on returns of Rs 1 lakh+ in a financial year.